TABLE 3

Mean costs and outcomes over the 12-month follow-up period

t-PADNasePlacebot-PA–DNase
Subjects44414845
Costs EUR
 Trial medications98622701213
 Initial hospital stay, nonsurgical7155±999111 164±27 89211 687±27 1335701±4604
 Initial hospital stay, surgical1953±88745401±17 2471113±4159234±1098
 Subsequent admissions511±20261065±6820682±2865102±682
 Total costs10 605±15 41317 856±34 86113 483±28 7987248±4922
Life-years gained0.988±0.0810.923±0.2280.969±0.1470.969±0.153
Cost-effectiveness of placebo versus trial interventions
 ICERt-PA dominantPlacebo dominantNAEUR 1.6 billion
 Probability placebo cost-effective0.240.81NA0.04

Data are presented as n or mean±sd. t-PA: tissue plasminogen activator; ICER: incremental cost-effectiveness ratio; NA: not applicable.